Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics

Core Insights - Labcorp reported $3.33 billion in revenue for Q4 2024, a year-over-year increase of 9.8% and a surprise of +0.44% over the Zacks Consensus Estimate of $3.32 billion [1] - The EPS for the same period was $3.45, compared to $3.30 a year ago, with an EPS surprise of +1.47% against the consensus estimate of $3.40 [1] Revenue Performance - Biopharma Laboratory Services generated $767 million, exceeding the estimated $747.52 million, representing a +10.4% change year-over-year [4] - Diagnostics Laboratories reported revenues of $2.59 billion, slightly above the estimated $2.57 billion, reflecting a +10.2% change compared to the previous year [4] Operating Income - Adjusted Operating Income for Biopharma Laboratory Services was $130.80 million, surpassing the average estimate of $123.15 million [4] - Adjusted Operating Income for Diagnostics Laboratories was $359.50 million, which fell short of the average estimate of $382.85 million [4] Stock Performance - Labcorp's shares have returned +6.7% over the past month, outperforming the Zacks S&P 500 composite's +2.1% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]